Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)

NCT03730662 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03730662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03730662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
November 20, 2018
Completion date
April 22, 2021
Enrollment
2,002 (actual)
Sites
216

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus